Powers John Joseph

EVP John Joseph Powers bought 131 BUSE shares at $28.19; stock now at $25.30, down -11.0% from 52-week high.

Powers purchased 131 shares at $28.19 on 2024-07-30, a modest transaction ($3,704.86 total value) that increased his position to 90,447 shares, or +0.1% relative to prior holdings. The buy occurred near BUSE's 52-week highs ($28.41), and the stock has since declined -11.0% from that peak, now trading at $25.30. At the BUSE-specific level, Powers' prior trades show mixed timing outcomes: his most recent transaction—a sell on 2024-07-05—posted a +8.7% 30-day return, while his previous two buys (2024-05-01) each returned -1.0% at 30 days before recovering to +21.7% at 90 days. The modest share count and size relative to his 90,447-share position suggest routine portfolio activity rather than a material conviction signal. His cross-ticker buy track record (7 prior buys, 71.43% 90-day win rate, +12.2% average 90-day return) indicates historical buy success, but the current -9.0% 90-day drawdown on BUSE and the stock's recent weakness merit attention to whether this trade marks accumulation at a fair entry or entry ahead of further headwinds.

EVP & General Counsel Powers sells 6,090 shares (43% of total sales value in filing) for $143,358.60 on 2024-07-05

Powers John Joseph executed a net sale of 5,917 shares, reducing his holdings by 27.7% (from 21,354 to 15,436 shares), following a pattern of modest purchases in May at $22.85 and then a substantial sale in July at $23.54. The filing contains 2 purchases totaling 172 shares for $3,937.07 and 1 sale totaling 6,090 shares for $143,358.60, representing a material reduction in his direct stake. Notably, 4 other insiders also bought BUSE within the past 14 days (cluster buy pattern), creating a divergence: while peers accumulated shares, the General Counsel was liquidating a significant portion. The stock currently trades at $23.88, within the 52-week range of $18.42–$25.41 and up 6.2% over 30 days, but his sales were priced below the current level, suggesting the timing was neither optimized for capturing subsequent gains nor indicative of advance adverse information.